ESTRADERM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESTRADERM (ESTRADERM).
Estradiol is a steroid hormone that binds to and activates estrogen receptors (ERα and ERβ), leading to transcriptional regulation of genes involved in reproductive, cardiovascular, skeletal, and central nervous system functions. It also has non-genomic effects via membrane-associated receptors.
| Metabolism | Primarily hepatic via CYP3A4-mediated oxidation. Undergoes enterohepatic recirculation. Metabolites include estrone, estriol, and conjugated estrogens (glucuronides and sulfates). |
| Excretion | Estradiol is primarily excreted in urine as glucuronide and sulfate conjugates (estrone, estriol, and their conjugates). Approximately 50-80% of a dose appears in urine, with 10-20% in feces via biliary elimination. |
| Half-life | The terminal elimination half-life of estradiol is approximately 1-2 hours for the parent drug. However, its active metabolite, estrone, has a longer half-life of about 12-24 hours, contributing to sustained clinical effects. |
| Protein binding | Estradiol is approximately 98-99% bound to plasma proteins, primarily sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | The volume of distribution is approximately 1.2 L/kg, indicating extensive distribution into tissues. For a 70 kg individual, Vd is ~84 L. |
| Bioavailability | Transdermal: Approximately 10-20% of the applied dose enters systemic circulation, avoiding first-pass metabolism. Oral bioavailability is <5% due to extensive hepatic first-pass effect. |
| Onset of Action | Transdermal: Therapeutic effects (e.g., relief of menopausal symptoms) are typically observed within 1-4 weeks of continuous use; maximal effects may take 2-3 months. |
| Duration of Action | Transdermal: Continuous application (e.g., twice-weekly patch changes) maintains steady serum levels; clinical effects persist with regular use. Steady-state is reached after 2-4 applications. |
| Molecular Weight | 272.38 |
Apply one transdermal patch delivering 0.05 mg estradiol per day twice weekly (every 3-4 days). Dose may be adjusted based on clinical response.
| Dosage form | SYSTEM |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment; data insufficient for severe renal impairment. |
| Liver impairment | Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution; no specific dose adjustment recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients; not recommended for use in children. |
| Geriatric use | Initiate at lowest effective dose (0.025 mg/day) due to increased risk of adverse effects such as thromboembolism and malignancy; monitor closely. |
| 1st trimester | Estradiol is contraindicated in pregnancy. Use during the first trimester is associated with a potential risk of fetal harm, including congenital anomalies such as cardiovascular and limb defects. |
| 2nd trimester | Use is contraindicated during the second trimester due to continued risk of fetal adverse effects. |
| 3rd trimester | Use is contraindicated during the third trimester due to risk of fetal harm and potential complications such as withdrawal bleeding in the neonate. |
Clinical note
Comprehensive clinical and safety monograph for ESTRADERM (ESTRADERM).
| Placental transfer | Estradiol crosses the placenta. The degree of transfer is significant, with fetal serum levels reaching approximately 50% of maternal levels. Studies show that estradiol and its metabolites are present in fetal tissues, which may pose risks for fetal development. |
| Breastfeeding | Estradiol is excreted in human milk in small amounts. Use during breastfeeding is generally not recommended as it may reduce milk production and quality. Limited data suggest no adverse effects on the nursing infant at low doses, but caution is advised. The American Academy of Pediatrics considers estradiol compatible with breastfeeding when used for postpartum lactation suppression, but not for hormone replacement therapy during lactation. |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. The Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50-79 years of age) receiving oral conjugated estrogens (0.625 mg/day) alone or in combination with medroxyprogesterone acetate relative to placebo. The Women's Health Initiative Memory Study (WHIMS) reported an increased risk of probable dementia in postmenopausal women 65 years of age or older receiving oral conjugated estrogens with or without medroxyprogesterone acetate. An increased risk of endometrial cancer has been reported with unopposed estrogen use in women with a uterus. Estrogens should be prescribed at the lowest effective dose and for the shortest duration consistent with treatment goals.
| Serious Effects |
Known or suspected pregnancyUndiagnosed abnormal genital bleedingKnown or suspected breast cancer (unless for palliative treatment)Known or suspected estrogen-dependent neoplasiaActive or past history of venous thromboembolism (e.g., deep vein thrombosis, pulmonary embolism)Active or past arterial thromboembolic disease (e.g., stroke, myocardial infarction)Known liver dysfunction or diseaseHypersensitivity to estradiol or any component of the productPorphyria
| Precautions |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - Limited data suggest no significant risk, but caution is advised. Alternatively, 'Safe' for short-term use as postpartum lactation suppression, but 'Avoid' for prolonged use. |
| Teratogenic Risk | FDA Pregnancy Category X. Estrogen use is contraindicated in pregnancy due to known risk of urogenital abnormalities in female fetuses and possible carcinogenic effects. First trimester exposure increases risk of vaginal adenosis and clear cell adenocarcinoma. Second and third trimester use associated with increased risk of congenital anomalies, including cardiac defects and limb reduction. Estrogens should not be used during pregnancy. |
| Fetal Monitoring | Monitor maternal blood pressure, weight, and signs of thromboembolism. Assess fetal growth and development if inadvertent exposure occurs. In cases of accidental use during pregnancy, perform ultrasound to evaluate for fetal anomalies. |
| Fertility Effects | Estradiol may inhibit ovulation by suppressing gonadotropin release, thereby reducing fertility. Use for contraception is intended; however, upon discontinuation, fertility usually returns. In assisted reproduction, estradiol is used to support endometrial growth. |
| Thromboembolic disorders: Increased risk of venous thromboembolism (VTE) and arterial thromboembolism (e.g., stroke, MI). Discontinue if VTE occurs., Cardiovascular disease: Increased risk of stroke and DVT in postmenopausal women; do not use for coronary heart disease prevention., Malignancy: Unopposed estrogen increases risk of endometrial cancer; addition of progestin mitigates risk. Increased risk of breast cancer, especially with combined therapy., Dementia: Increased risk of probable dementia in women ≥65 years (WHIMS study)., Gallbladder disease: Increased risk requiring surgery., Hypertriglyceridemia: Consider discontinuation if pancreatitis occurs., Fluid retention: Monitor patients with conditions affected by edema (e.g., cardiac/renal impairment)., Hypocalcemia: Use caution in patients with hypoparathyroidism., Endometriosis: May exacerbate disease., Hepatic impairment: Contraindicated in acute or chronic liver disease., Ocular abnormalities: Discontinue if sudden vision loss or papilledema occurs., Pregnancy: Not indicated; estrogens cause fetal harm., Lactation: Use with caution; excreted in breast milk. |
| Food/Dietary | Grapefruit and grapefruit juice may increase estrogen exposure; limit intake. No other significant food interactions. Avoid excessive alcohol as it may impair liver metabolism. |
| Clinical Pearls | Apply patch to clean, dry, intact skin on lower trunk (avoid waistline). Rotate application sites with 1-week interval between same site. Matrix patches (e.g., Climara) deliver drug over 7 days; reservoir patches (e.g., Estraderm) deliver over 3-4 days and should not be cut. Use lowest effective dose for shortest duration. Monitor for endometrial hyperplasia if uterus intact; consider progestin co-therapy. Avoid application to breasts or areas with lotion/oil. |
| Patient Advice | Apply patch to clean, dry skin on lower abdomen or buttocks; do not apply to breasts or oily/irritated skin. · Rotate application sites; do not use same spot more than once a week. · Press firmly for 10 seconds; ensure edges adhere; if patch falls off, apply a new one and continue same schedule. · Replace patch twice weekly (e.g., every 3-4 days) for reservoir patches; once weekly for matrix patches. · Do not cut or trim the patch; discard used patches out of reach of children and pets. · Report signs of blood clots (leg pain, chest pain, sudden shortness of breath), stroke (sudden severe headache, vision/speech changes), or skin irritation. · Use a non-hormonal backup contraceptive if needed; estrogen alone does not prevent pregnancy. |